Transcription Start Regions in the Human Genome Are Favored Targets for MLV Integration
The DOI matches its Crossref record; 17 of the 18 references it cites were found in a registry or an index.
Abstract
Factors contributing to retroviral integration have been intractable because past studies have not precisely located genomic sites of proviruses in sufficient numbers for significant analysis. In this study, 903 murine leukemia virus (MLV) and 379 human immunodeficiency virus–1 (HIV-1) integrations in the human genome were mapped. The data showed that MLV preferred integration near the start of transcriptional units (either upstream or downstream) whereas HIV-1 preferred integration anywhere in the transcriptional unit but not upstream of the transcriptional start. Defining different integration site preferences for retroviruses will have important ramifications for gene therapy and may aid in our understanding of the factors directing the integration process.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The well-understood integration preferences of HIV-1 for active transcription units72 and MLV for promoter/enhancer regions73–75 are in large part dictated via specific interactions of the respective IN proteins with chromatin-bound host factors.”
From Structure and function of retroviral integrase (2022) · cites this paper as [73]
In the citing paper
“Multiple studies now indicate that gammaretroviral vectors such as the vectors used in the two SCID-X1 trials preferentially integrate into the 5′ end of genes, near the transcription start sites[47].”
From Finding the needle in the hay stack: Hematopoietic stem cells in Fanconi anemia (2009) · cites this paper as [47]
In the citing paper
“Finally, the preferred sequences of the genome for integration are different from the γ-RVV, with LVV preferentially integrating in genes and introns away for transcriptional start sites preferred by γ-RVV.20”
From Ex vivo modification of hematopoietic stem and progenitor cells for gene therapy (2025) · cites this paper as [20]
Citations
Cites
CpG-rich islands and the function of DNA methylation
Bird, A. P. (1986) · Nature · doi:10.1038/321209a0 · Cited by 3,777
Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
Cavazzana-Calvo, M., Hacein-Bey, S., Basile, G. D. S., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J.-L., et al. (2000) · Science · doi:10.1126/science.288.5466.669 · Cited by 2,167
HIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots
Schröder, A. R. W., Shinn, P., Chen, H., Berry, C., Ecker, J. R., & Bushman, F. (2002) · Cell · doi:10.1016/s0092-8674(02)00864-4 · Cited by 1,832
Sustained Correction of X-Linked Severe Combined Immunodeficiency by ex Vivo Gene Therapy
Hacein-Bey-Abina, S., Le Deist, F., Carlier, F., Bouneaud, C., Hue, C., De Villartay, J.-P., Thrasher, A. J., Wulffraat, N., Sorensen, R., Dupuis-Girod, S., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012616 · Cited by 1,058
CpG islands as gene markers in the human genome
Larsen, F., Gundersen, G., Lopez, R., & Prydz, H. (1992) · Genomics · doi:10.1016/0888-7543(92)90024-m · Cited by 922
Pryciak, P. M., & Varmus, H. E. (1992) · Cell · doi:10.1016/0092-8674(92)90289-o · Cited by 273
Introducing RefSeq and LocusLink: curated human genome resources at the NCBI
Pruitt, K. D., Katz, K. S., Sicotte, H., & Maglott, D. R. (2000) · Trends in Genetics · doi:10.1016/s0168-9525(99)01882-x · Cited by 241
Check, E. (2002) · Nature · doi:10.1038/420116a · Cited by 238
Pruss, D., Bushman, F. D., & Wolffe, A. P. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.13.5913 · Cited by 236
Transcriptionally active genome regions are preferred targets for retrovirus integration
Scherdin, U., Rhodes, K., & Breindl, M. (1990) · Journal of Virology · doi:10.1128/jvi.64.2.907-912.1990 · Cited by 210
Research works printed but not linked: 2
- National Center for Biotechnology Information Reference Sequence Project (RefSeq) www.ncbi.nlm.nih.gov/RefSeq/.
- The database is available online at www.ncbi.nlm.nih.gov/geo/.
Cited by
Items 301–400 of 1,000
Sleeping Beauty Transposition From Nonintegrating Lentivirus
Vink, C. A., Gaspar, H. B., Gabriel, R., Schmidt, M., McIvor, R. S., Thrasher, A. J., & Qasim, W. (2009) · Molecular Therapy · doi:10.1038/mt.2009.94 · Cited by 74
Use of HIV as a gene transfer vector.
Pluta, K., & Kacprzak, M. (2009) · Acta Biochimica Polonica · doi:10.18388/abp.2009_2490 · Cited by 69
“A serious drawback of using onco-retroviruses in clinical trials is their natural disposition to integrate near promoters and regulatory regions (Wu et al., 2003; De Palma et al., 2005; Tsukahara et al., 2006; Deichmann et al., 2007; reviewed in Daniel & Smith, 2008) and to induce insertional…”
BackgroundShin, M. S., Fredrickson, T. N., Hartley, J. W., Suzuki, T., Agaki, K., & Morse, H. C. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3885 · Cited by 76
“In a study of over 900 different MuLV RIS in human HeLa cells, it was shown that there was preferential integration in proximity to the start sites of transcriptionally active genes ( 46 ); 34.2% of integrations were within genes, 11.2% were within 5-kb upstream of genes, and 3.4% were within 5-kb downstream of genes.”
BackgroundInfluentialDelelis, O., Lehmann‐Che, J., & Saïb, A. (2004) · Current Opinion in Microbiology · doi:10.1016/j.mib.2004.06.009 · Cited by 90
Crise, B., Li, Y., Yuan, C., Morcock, D. R., Whitby, D., Munroe, D. J., Arthur, L. O., & Wu, X. (2005) · Journal of Virology · doi:10.1128/jvi.79.19.12199-12204.2005 · Cited by 73
“MLV favors integration at or near promoter regions of genes as defined by CpG islands or transcription start sites of genes (43).”
BackgroundMethodInfluentialSelf-citationde Andrés-Aguayo, L., Varas, F., Kallin, E. M., Infante, J. F., Wurst, W., Floss, T., & Graf, T. (2011) · Blood · doi:10.1182/blood-2010-12-322081 · Cited by 75
Silvers, R. M., Smith, J. A., Schowalter, M., Litwin, S., Liang, Z., Geary, K., & Daniel, R. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.134 · Cited by 72
“However, more recent analyses, which involved large-scale cloning and sequencing of integration sites, demonstrated that the MLV-based vectors preferentially integrate in promoter regions (Wu et al. , 2003).”
HIV-1 regulation of latency in the monocyte-macrophage lineage and in CD4+ T lymphocytes
Redel, L., Douce, V. L., Cherrier, T., Marban, C., Janossy, A., Aunis, D., Lint, C. M. V., Rohr, O., & Schwartz, C. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0409264 · Cited by 78
“preferentially integrate into actively transcribed genes [78, 79]”
Rapid spread of mouse mammary tumor virus in cultured human breast cells
Indik, S., Günzburg, W. H., Kulich, P., Salmons, B., & Rouault, F. (2007) · Retrovirology · doi:10.1186/1742-4690-4-73 · Cited by 81
“Integration site detection Integration sites were determined as described previously [15].”
MethodInfluentialWhat Integration Sites Tell Us about HIV Persistence
Hughes, S. H., & Coffin, J. M. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.04.010 · Cited by 80
“HIV integration favors the bodies of actively expressed genes (Schröder et al., 2002); MLV favors active enhancer sequences upstream of genes (De Ravin et al., 2014; LaFave et al., 2014; Wu et al., 2003).”
Current perspectives in zebrafish reverse genetics: Moving forward
Skromne, I., & Prince, V. (2008) · Developmental Dynamics · doi:10.1002/dvdy.21484 · Cited by 74
“Linker-mediated PCR can then be performed with one primer specific to the vector and the other primer specific to the linker (Wu et al., 2003; Ellingsen et al., 2005).”
BackgroundIntegration Site Selection by Retroviral Vectors: Molecular Mechanism and Clinical Consequences
Daniel, R., & Smith, J. A. (2008) · Human Gene Therapy · doi:10.1089/hum.2007.148 · Cited by 73
“However, integration is not random (Schroder et al ., 2002; Wu et al ., 2003; Mitchell et al ., 2004).”
Suerth, J. D., Maetzig, T., Brugman, M. H., Heinz, N., Appelt, J.-U., Kaufmann, K. B., Schmidt, M., Grez, M., Modlich, U., Baum, C., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2011.309 · Cited by 73
Self-Inactivating Alpharetroviral Vectors with a Split-Packaging Design
Suerth, J. D., Maetzig, T., Galla, M., Baum, C., & Schambach, A. (2010) · Journal of Virology · doi:10.1128/jvi.00182-10 · Cited by 88
Viruses and Human Breast Cancer
Lawson, J. S., Günzburg, W. H., & Whitaker, N. J. (1972) · The Lancet · doi:10.1016/s0140-6736(72)92848-6 · Cited by 74
Gene therapy for chronic granulomatous disease
Barese, C. N., Goebel, W. S., & Dinauer, M. C. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.9.1423 · Cited by 71
“A recent development of relevance to refining approaches for gene therapy is the recognition that both oncoretroviral and lentiviral vectors frequently integrate in or near genes [97,98], with the potential for disruption or alteration of cellular gene function, including effects of potent viral enhancers present in t…”
BackgroundA method to sequence and quantify DNA integration for monitoring outcome in gene therapy
Brady, T., Roth, S. L., Malani, N., Wang, G. P., Berry, C. C., Leboulch, P., Hacein-Bey-Abina, S., Cavazzana-Calvo, M., Papapetrou, E. P., Sadelain, M., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr140 · Cited by 71
“Sites of integration were identified by sequencing PCR products from a primer bound to the vector DNA, so that the sequence read extended into the flanking human DNA (13,14).”
MethodFibroblast-Derived Induced Pluripotent Stem Cells Show No Common Retroviral Vector Insertions
Varas, F., Stadtfeld, M., de Andrés-Aguayo, L., Maherali, N., Tullio, A. D., Pantano, L., Notredame, C., Hochedlinger, K., & Graf, T. (2008) · Stem Cells · doi:10.1634/stemcells.2008-0696 · Cited by 73
Development of gene therapy for blood disorders
Nienhuis, A. W. (2008) · Blood · doi:10.1182/blood-2007-11-078121 · Cited by 78
Lagresle‐Peyrou, C., Yates, F., Malassis-Séris, M., Hue, C., Morillon, E., Garrigue, A., Liu, A. P., Hajdari, P., Stockholm, D., Danos, O., et al. (2005) · Blood · doi:10.1182/blood-2005-05-2032 · Cited by 73
Guo, Y., & Levin, H. L. (2010) · Genome Research · doi:10.1101/gr.099648.109 · Cited by 72
“As developed for sequencing insertion sites of human immunodeficiency virus 1, (HIV-1) and murine leukemia virus (MLV), we applied ligationmediated PCR to generate libraries of Tf1-neo associated with the downstream flanking DNA (Schroder et al. 2002; Wu et al. 2003).”
MethodAiyer, S., Swapna, G. V. T., Malani, N., Aramini, J. M., Schneider, W. M., Plumb, M. R., Ghanem, M., Larue, R. C., Sharma, A., Studamire, B., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku175 · Cited by 72
“However, despite the efficiency in gene delivery, insertional mutagenesis can result in clonal expansion of cells bearing specific integrants (2), associated with the preferential integration of murine leukemia virus (MLV) vectors upstream of transcription start sites (TSS) and CpG islands near promoter regions (3).”
BackgroundCurtin, J. A., Dane, A. P., Swanson, A., Alexander, I. E., & Ginn, S. L. (2008) · Gene Therapy · doi:10.1038/sj.gt.3303105 · Cited by 82
Ronen, K., Negre, O., Roth, S., Colomb, C., Malani, N., Denaro, M., Brady, T., Fusil, F., Gillet-Legrand, B., Hehir, K., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.20 · Cited by 71
“7,13 γ-Retroviral vectors show a strong propensity to integrate at promoters and gene 5 ′ ends, 14 and clustering near genes controlling cell growth and proliferation has been reported.”
Demeulemeester, J., De Rijck, J., Gijsbers, R., & Debyser, Z. (2015) · BioEssays · doi:10.1002/bies.201500051 · Cited by 71
Starr, T. K., Scott, P. M., Marsh, B. M., Zhao, L. Q., Than, B. L. N., O’Sullivan, M. G., Sarver, A. L., Dupuy, A. J., Largaespada, D. A., & Cormier, R. T. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018012108 · Cited by 80
“Linkers [described previously (42)] were ligated to NlaIII- (right-side) or BfaI- (left side) digested genomic DNA using T4 DNA ligase.”
MethodThe Chimeric Antigen Receptor Detection Toolkit
Hu, Y., & Huang, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01770 · Cited by 77
“Historically, integration site analysis employed restriction enzymes to fragment gDNA (18).”
MethodTrobridge, G. D., Beard, B. C., Gooch, C., Wohlfahrt, M. E., Olsen, P., Fletcher, J., Malik, P., & Kiem, H. (2008) · Blood · doi:10.1182/blood-2007-09-115022 · Cited by 72
Larcher, F., Dellambra, E., Rico, L., Bondanza, S., Murillas, R., Cattoglio, C., Mavilio, F., Jorcano, J. L., Zambruno, G., & Del Rio, M. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300238 · Cited by 68
Slape, C. I., Hartung, H. D., Lin, Y., Bies, J., Wolff, L., & Aplan, P. D. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0075 · Cited by 73
Botbol, Y., Raghavendra, N. K., Rahman, S., Engelman, A., & Lavigne, M. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm1127 · Cited by 63
Gammaretroviral Integration into Nucleosomal Target DNA In Vivo
Roth, S. L., Malani, N., & Bushman, F. D. (2011) · Journal of Virology · doi:10.1128/jvi.00635-11 · Cited by 69
“transcription start sites (8, 9, 14, 17, 33, 56, 61) and regions less”
BackgroundTranscription activator like effector (TALE)-directed piggyBac transposition in human cells
Owens, J. B., Mauro, D., Stoytchev, I., Bhakta, M. S., Kim, M., Segal, D. J., & Moisyadi, S. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt677 · Cited by 75
“A system that could safely direct insertions to genomic safe harbors would overcome the strong preference for the disruption of active genes that burdens viralbased approaches (5,7,8), thereby transforming the gene therapy field.”
BackgroundLi, X., Ewis, H. E., Hice, R. H., Malani, N., Parker, N., Zhou, L., Feschotte, C., Bushman, F. D., Atkinson, P. W., & Craig, N. L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121543109 · Cited by 81
“MLV strongly favors integration near gene 5′ ends (28) (Fig.”
BackgroundFoamy virus vectors for gene transfer
Trobridge, G. D. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903246388 · Cited by 73
“The FV vector integration profile differs from both MLV, which integrates preferentially near transcription start sites [86], and HIV-1 vectors, which integrate preferentially in transcribed genes [87].”
BackgroundRahman, S., Lu, R., Vandegraaff, N., Cherepanov, P., & Engelman, A. (2006) · Virology · doi:10.1016/j.virol.2006.08.011 · Cited by 73
Papayannakos, C. J., & Daniel, R. (2012) · Gene Therapy · doi:10.1038/gt.2012.88 · Cited by 75
Ramezani, A., Hawley, T. S., & Hawley, R. G. (2008) · Stem Cells · doi:10.1634/stemcells.2008-0258 · Cited by 66
Effect of chromatin upon Agrobacterium T-DNA integration and transgene expression
Gelvin, S. B., & Kim, S. (2007) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/j.bbaexp.2007.04.005 · Cited by 78
Ciuffi, A., Mitchell, R. S., Hoffmann, C., Leipzig, J., Shinn, P., Ecker, J. R., & Bushman, F. D. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.10.009 · Cited by 65
Leoni, C., Volpicella, M., Leo, F. D., Gallerani, R., & Ceci, L. R. (2011) · FEBS Journal · doi:10.1111/j.1742-4658.2011.08307.x · Cited by 74
Kerns, H. M. M., Ryu, B. Y., Stirling, B., Sather, B. D., Astrakhan, A., Humblet‐Baron, S., Liggitt, D., & Rawlings, D. J. (2010) · Blood · doi:10.1182/blood-2009-09-241869 · Cited by 70
“In contrast, MOI 15 to 100 consistently restored B-cell numbers, and similar rescue was observed using “medium” (15-25) versus “high” (50-100) MOI (4 independent experiments).”
ResultCiuffi, A., Diamond, T. L., Hwang, Y., Marshall, H. M., & Bushman, F. D. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.960 · Cited by 62
Kelley, D. Z., Flam, E. L., Izumchenko, E., Danilova, L., Wulf, H. A., Guo, T. W., Singman, D. A., Afsari, B., Skaist, A. M., Considine, M., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0833 · Cited by 76
“Published data suggest that integration of different viruses correlates with an "open chromatin" landscape (50, 51).”
BackgroundBovine leukemia virus integration site selection in cattle that develop leukemia
Murakami, H., Yamada, T., Suzuki, M. M., Nakahara, Y., Suzuki, K., & Sentsui, H. (2011) · Virus Research · doi:10.1016/j.virusres.2011.01.004 · Cited by 69
“Therefore, integration near ranscription start sites and CpG islands was found with low freuency, in contrast to the MLV provirus, which favors integration ear transcription start sites (Wu et al., 2003).”
ResultUpping the Ante: Recent Advances in Direct Reprogramming
Müller, L. U., Daley, G. Q., & Williams, D. A. (2009) · Molecular Therapy · doi:10.1038/mt.2009.72 · Cited by 65
Viral Vector–mediated and Cell-based Therapies for Treatment of Cystic Fibrosis
Flotte, T. R., Ng, P., Dylla, D. E., McCray, P. B., Wang, G., Kolls, J. K., & Hu, J. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300002 · Cited by 72
Viral Vectors in Cancer Immunotherapy: Which Vector for Which Strategy?
Collins, S., Guinn, B., Harrison, P. T., Scallan, M. F., O’Sullivan, G. C., & Tangney, M. (2008) · Current Gene Therapy · doi:10.2174/156652308784049345 · Cited by 73
“A number of other strategies have been studied to reduce the risk of insertional mutagenesis, such as the use of genetic insulators or cell specific regulatory elements [113-115].”
BackgroundRetrovirus and lentivirus vector design and methods of cell conditioning
Cooray, S., Howe, S. J., & Thrasher, A. J. (2012) · Methods in Enzymology · doi:10.1016/b978-0-12-386509-0.00003-x · Cited by 65
“Gammaretroviral vectors have a propensity to integrate near regulatory regions (including transcription start sites) of active genes (De et al., 2005; Wu et al., 2003).”
BackgroundHughes, S. H. (2004) · Folia Biologica · doi:10.14712/fb2004050030107 · Cited by 102
Gene therapy for primary immunodeficiencies
Fischer, A., Hacein‐Bey‐Abina, S., Touzot, F., & Cavazzana, M. (2015) · Clinical Genetics · doi:10.1111/cge.12576 · Cited by 67
“It has since been shown that γRVs integrate ‘semi-randomly’ with a preference for active genes, with an equal distribution between the promoter region and the transcribed region (27, 28, 30, 31).”
BackgroundSleeping Beauty-mediated down-regulation of huntingtin expression by RNA interference
Chen, Z. J., Kren, B. T., Wong, P. Y.-P., Low, W. C., & Steer, C. J. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.02.024 · Cited by 66
“While SB Tns insert nearly randomly into TA dinucleotides in the genome [21,22], retroviruses integrate preferentially into promoter regions [ 23 ], and lentiviruses into transcriptional units [24].”
BackgroundRetargeting Sleeping Beauty Transposon Insertions by Engineered Zinc Finger DNA-binding Domains
Voigt, K., Gogol‐Döring, A., Miskey, C., Chen, W., Cathomen, T., Izsvák, Z., & Ivics, Z. (2012) · Molecular Therapy · doi:10.1038/mt.2012.126 · Cited by 70
Cassani, B., Montini, E., Maruggi, G., Ambrosi, A., Mirolo, M., Selleri, S., Biral, E., Frugnoli, I., Hernandez-Trujillo, V., Di Serio, C., et al. (2009) · Blood · doi:10.1182/blood-2009-02-202085 · Cited by 65
Viruses and Human Breast Cancer
Lawson, J. S., Günzburg, W. H., & Whitaker, N. J. (2006) · Future Microbiology · doi:10.2217/17460913.1.1.33 · Cited by 69
“HHV8 is known to act synergistically with HIV to cause Kaposi’s sarcoma [108].”
BackgroundInfluentialLi, W., Singh, P. K., Sowd, G. A., Bedwell, G. J., Jang, S., Achuthan, V., Oleru, A. V., Wong, D., Fadel, H. J., Lee, K., et al. (2020) · mBio · doi:10.1128/mbio.02254-20 · Cited by 64
“As expected (9), the length normalized MLV curve in WT cells spiked sharply in the 5= end region, with”
InfluentialMétais, J.-Y., & Dunbar, C. E. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300372 · Cited by 64
Trobridge, G. D., Wu, R. A., Beard, B. C., Chiu, S. Y., Muñoz, N. M., von Laer, D., Rossi, J. J., & Kiem, H. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007693 · Cited by 64
“Lentiviral vectors may also be safer than gammaretroviral vectors [50] based in part on differences in their integration profile [51,52].”
BackgroundThe cell biology of HIV-1 and other retroviruses
Freed, E. O., & Mouland, A. J. (2006) · Retrovirology · doi:10.1186/1742-4690-3-77 · Cited by 60
“found that transcription units are favored for HIV-1 integration [19,20]; in contrast, MLV prefers to integrate at transcription start sites [21] whereas avian sarcoma-leukosis virus (ASLV) integration sites are nearly random [19,22].”
BackgroundInsertional mutagenesis strategies in zebrafish
Sivasubbu, S., Balciunas, D., Amsterdam, A., & Ekker, S. C. (2007) · Genome Biology · doi:10.1186/gb-2007-8-s1-s9 · Cited by 64
“In part because of a preference of Maloneybased viruses to insert near to the 5’ end of genes [34,35], most of these insertions are in the first intron.”
BackgroundRetargeting transposon insertions by the adeno-associated virus Rep protein
Ammar, I., Gogol‐Döring, A., Miskey, C., Chen, W., Cathomen, T., Izsvák, Z., & Ivics, Z. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks317 · Cited by 69
“Similar studies showed that the murine leukaemia virus (MLV) has a strong preference for integrating into regions surrounding transcription start sites (3).”
Chimeric piggyBac transposases for genomic targeting in human cells
Owens, J. B., Urschitz, J., Stoytchev, I., Dang, N. C., Stoytcheva, Z., Belcaid, M., Maragathavally, K. J., Coates, C. J., Segal, D. J., & Moisyadi, S. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks309 · Cited by 60
Amplification, Next-generation Sequencing, and Genomic DNA Mapping of Retroviral Integration Sites
Serrao, E., Cherepanov, P., & Engelman, A. N. (2016) · Journal of Visualized Experiments · doi:10.3791/53840 · Cited by 53
Yoshida, J., Akagi, K., Misawa, R., Kokubu, C., Takeda, J., & Horie, K. (2017) · Scientific Reports · doi:10.1038/srep43613 · Cited by 66
Relationship between retroviral DNA-integration-site selection and host cell transcription
Maxfield, L. F., Fraize, C. D., & Coffin, J. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409204102 · Cited by 63
Hackett, C. S., Geurts, A. M., & Hackett, P. B. (2007) · Genome biology · doi:10.1186/gb-2007-8-s1-s12 · Cited by 73
Key determinants of target DNA recognition by retroviral intasomes
Serrao, E., Ballandras-Colas, A., Cherepanov, P., Maertens, G. N., & Engelman, A. N. (2015) · Retrovirology · doi:10.1186/s12977-015-0167-3 · Cited by 62
“Lentiviruses preferentially integrate along the bodies of actively transcribed genes [19], whereas the gammaretroviruses favor transcriptional start sites (TSSs) and active enhancer regions [20-22].”
BackgroundGene therapy for inherited immunodeficiency
Touzot, F., Hacein‐Bey‐Abina, S., Fischer, A., & Cavazzana, M. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.895811 · Cited by 66
Viral Integration and Consequences on Host Gene Expression
Desfarges, S., & Ciuffi, A. (2012) · Springer eBooks · doi:10.1007/978-94-007-4899-6_7 · Cited by 80
“…MLV vectors preferentially integrate at promoters and regions close to the transcription start site (Kim et al. 2008, 2011 ; Mitchell et al. 2004 ; Wu et al. 2003 ) , exon 1 of LMO2 locus was shown to be a hotspot for MLV integration in T cells, with 1 integration out of 2.125 ´ 10 5 (Yamada et…”
BackgroundInfluentialWilliams, D. A., & Thrasher, A. J. (2014) · Stem Cells Translational Medicine · doi:10.5966/sctm.2013-0206 · Cited by 56
Redefining the common insertion site
Wu, X., Luke, B. T., & Burgess, S. M. (2005) · Virology · doi:10.1016/j.virol.2005.08.047 · Cited by 69
“We previously demonstrated that MLV integrations are biased towards genes with higher expression levels (Wu et al., 2003) and the integration mapping was done in the tumor derived HeLa cells.”
BackgroundSelf-citationBender, A. M., Collier, L. S., Rodríguez, F. J., Tieu, C., Larson, J. D., Halder, C., Mahlum, E., Kollmeyer, T. M., Akagi, K., Sarkar, G., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4674 · Cited by 63
“3558 (13) with the following modifications: primary PCR products were purified using the Genelute system (Sigma) and diluted 1:25 before secondary PCR.”
Generation of a fluorescently labeled endogenous protein library in living human cells
Sigal, A., Danon, T., Cohen, A., Milo, R., Geva‐Zatorsky, N., Lustig, G., Liron, Y., Alon, U. S., & Perzov, N. (2007) · Nature Protocols · doi:10.1038/nprot.2007.197 · Cited by 64
“This bias for the N terminus is probably due to the generally large size of the first intron, and the known preference of MoMLV to integrate near the start of gene”
BackgroundIntracellular trafficking of retroviral vectors: obstacles and advances
Anderson, J. L., & Hope, T. J. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302591 · Cited by 75
Moalic, Y., Blanchard, Y., Felix, H. S., & Jestin, A. (2006) · Journal of Virology · doi:10.1128/jvi.00904-06 · Cited by 67
“Several genome-wide studies of retroviral DNA integration have recently been carried out on the complete human genome sequence (12, 21, 32, 34, 43, 54).”
BackgroundResultInfluentialRNA-guided retargeting of Sleeping Beauty transposition in human cells
Kovač, A., Miskey, C., Menzel, M., Grueso, E., Gogol‐Döring, A., & Ivics, Z. (2020) · eLife · doi:10.7554/elife.53868 · Cited by 64
“For example, lentiviral or g -retroviral vectors actively target genes or transcriptional start sites ( Schro¨der et al., 2002 ; Cohn et al., 2015 ; Wu et al., 2003 ; Cattoglio et al., 2010 ; Mitchell et al., 2004 ).”
BackgroundInsertional mutagenesis in mice: new perspectives and tools
Carlson, C. M., & Largaespada, D. A. (2005) · Nature Reviews Genetics · doi:10.1038/nrg1638 · Cited by 75
“As mentioned above, transposons also provide a novel means for integrating gene traps in ES cells without the risk for the deletions or insertion site preferences that are observed with plasmid or virus integration of trap”
BackgroundTaganov, K. D., Cuesta, I., Daniel, R., Cirillo, L. A., Katz, R. A., Zaret, K. S., & Skalka, A. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.11.5848-5855.2004 · Cited by 57
“Further characterization of a large number of murine leukemia virus (MLV) and HIV-1 integration sites have indicated that MLV is integrated preferentially near the start of actively transcribed genes, whereas HIV-1 shows a bias for integration in many places within such genes but not in the transcriptional start regio…”
BackgroundInflammatory bowel disease: Therapeutic limitations and prospective of the stem cell therapy
Mishra, R., Dhawan, P., Srivastava, A. S., & Singh, A. B. (2020) · World Journal of Stem Cells · doi:10.4252/wjsc.v12.i10.1050 · Cited by 63
Nonviral Gene Delivery with the Sleeping Beauty Transposon System
Ivics, Z., & Izsvák, Z. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.143 · Cited by 64
“Such risk is especially pronounced with gammaretroviral vectors based on the murine leukemia virus (MLV) that preferentially integrate into transcription start sites (Wu et al. , 2003).”
Benjelloun, F., Garrigue, A., Demerens, C., Soulas-Sprauel, P., Malassis-Séris, M., Stockholm, D., Hauer, J., Blondeau, J., Rivière, J., Lim, A., et al. (2008) · Molecular Therapy · doi:10.1038/mt.2008.118 · Cited by 61
A Mammalian enhancer trap resource for discovering and manipulating neuronal cell types
Shima, Y., Sugino, K., Hempel, C. M., Shima, M., Taneja, P., Bullis, J. B., Mehta, S., Lois, C., & Nelson, S. B. (2016) · eLife · doi:10.7554/elife.13503 · Cited by 63
“Amplification of insertion sites by ligation mediated (LM)-PCR was performed as described by Wu et al. (Wu et al., 2003).”
MethodPreventing and exploiting the oncogenic potential of integrating gene vectors
Modlich, U., & Baum, C. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38831 · Cited by 61
Pandey, K. K., Sinha, S., & Grandgenett, D. P. (2007) · Journal of Virology · doi:10.1128/jvi.02322-06 · Cited by 58
“Major advances have occurred in identifying target sites and understanding the basis for target site selectivity exhibited by human immunodeficiency virus type 1 (HIV-1), murine leukemia virus (MLV), and avian sarcoma-leukemia virus in human chromosomes (25, 34, 36, 37, 51).”
BackgroundChromatin dynamics associated with HIV-1 Tat-activated transcription
Easley, R., Duyne, R. V., Coley, W., Guendel, I., Dadgar, S., Kehn‐Hall, K., & Kashanchi, F. (2009) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2009.08.008 · Cited by 60
Torres‐Torronteras, J., Gómez, A., Eixarch, H., Palenzuela, L., Pizzorno, G., Hirano, M., Andreu, A. L., Barquinero, J., & Martí, R. (2011) · Gene Therapy · doi:10.1038/gt.2011.24 · Cited by 60
Inhibition of Early Steps of HIV-1 Replication by SNF5/Ini1
Maroun, M., Delelis, O., Coadou, G., Bader, T., Ségéral, E., Mbemba, G., Petit, C., Sonigo, P., Rain, J., Mouscadet, J. F., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604849200 · Cited by 66
LDLR-Gene therapy for familial hypercholesterolaemia: problems, progress, and perspectives
Al-Allaf, F. A., Coutelle, C., Waddington, S. N., David, A. L., Harbottle, R. P., & Themis, M. (2010) · International Archives of Medicine · doi:10.1186/1755-7682-3-36 · Cited by 70
Ninova, M., Godneeva, B. K., Chen, Y.-C. A., Luo, Y., Prakash, S. J., Jankovics, F., Erdélyi, M., Aravin, A. A., & Tóth, K. F. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.09.033 · Cited by 63
Toolbox for retrovectorologists
Pagès, J., & Bru, T. (2004) · The Journal of Gene Medicine · doi:10.1002/jgm.498 · Cited by 72
“confirmed that gene vicinity appears to offer favoured sites for retroviral integration [142].”
BackgroundSerrao, E., Krishnan, L., Shun, M.-C., Li, X., Cherepanov, P., Engelman, A., & Maertens, G. N. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku136 · Cited by 59
Lentiviral Vectors for the Treatment and Prevention of Cystic Fibrosis Lung Disease
Marquez Loza, L. I., Yuen, E. C., & McCray, P. B. (2019) · Genes · doi:10.3390/genes10030218 · Cited by 59
“γ-retroviral integration is enriched near enhancer and promoter regions of actively transcribed genes [55,58].”
BackgroundHos2 and Set3 Promote Integration of Ty1 Retrotransposons at tRNA Genes in Saccharomyces cerevisiae
Mou, Z., Kenny, A. E., & Curcio, M. J. (2006) · Genetics · doi:10.1534/genetics.105.054072 · Cited by 58
Millington, M., Arndt, A. J., Boyd, M. P., Applegate, T. L., & Shen, S. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006461 · Cited by 68
Pelascini, L. P. L., Janssen, J. M., & Gonçalves, M. A. F. V. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.069 · Cited by 57
“These were related to the pathogenic nature of the parental viruses and to the risk associated with the biased integration of vector genomes into transcriptionally active host genes (Schröder et al., 2002; Wu et al., 2003).”
BackgroundDevelopment of lentiviral gene therapy for Wiskott Aldrich syndrome
Galy, A. H. M., Roncarolo, M., & Thrasher, A. J. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.2.181 · Cited by 65
“to integrate close to the start of transcriptional units [65-67].”
BackgroundGene Therapy Applications of Non-Human Lentiviral Vectors
Munis, A. M. (2020) · Viruses · doi:10.3390/v12101106 · Cited by 62
Shigeoka, T. (2005) · Nucleic Acids Research · doi:10.1093/nar/gni022 · Cited by 59
“Rather, ES cell clones which integrated the UPATrap vector near the 50 end of genes were frequently isolated, probably reflecting the integration-site preference of Moloney murine leukemia virus ( 23 ).”
BackgroundWitherspoon, D. J., Zhang, Y., Xing, J., Watkins, W. S., Ha, H., Batzer, M. A., & Jorde, L. B. (2013) · Genome Research · doi:10.1101/gr.148973.112 · Cited by 58
Tumor cells escape suicide gene therapy by genetic and epigenetic instability
Frank, O. (2004) · Blood · doi:10.1182/blood-2004-03-0852 · Cited by 57
Metadata
- Authors
- Wu, X., Li, Y., Crise, B., & Burgess, S. M.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Burgess, Shawn M.
- Venue
- Science
- Published
- 2003-06-13
- Volume
- 300
- Issue
- 5626
- Pages
- 1749-1751
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1637867377
- Cited by
- 1,305
- References
- 18
- Citations by year
- 2026: 9 · 2025: 10 · 2024: 11 · 2023: 13 · 2022: 18 · 2021: 25 · 2020: 27 · 2019: 33 · 2018: 24 · 2017: 39 · 2016: 43 · 2015: 49 · 2014: 65 · 2013: 51 · 2012: 83
- FWCI
- 57.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (n01co12400-79-0-22)
- National Cancer Institute (N01CO12400)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Chromosomal and Genetic Variations
- Keywords
- retroviral integration, transcription start sites, murine leukemia virus, HIV-1, human genome, gene therapy
- MeSH terms
- Child, Genetic Vectors, HeLa Cells, Humans, Leukemia, Leukemia Virus, Murine, Promoter Regions, Genetic, Transcription, Genetic, Tumor Cells, Cultured, Genetic Therapy, HIV-1, Gene Expression, Genome, Human, Virus Integration, CpG Islands, Oligonucleotide Array Sequence Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.